Tuesday, May 1, 2018

**TIME** | **#** | **MAIN SESSION** | **TITLE** | **LOCATION** | **PRESENTER** | **AUTHOR BLOCK** | **TRACK** | **SCIENTIFIC SECTION**
---|---|---|---|---|---|---|---|---
08:30 AM - 09:45 AM | A0118 | A0118 | Diabetic retinal disease: key findings and current controversies | Room 100 | Mark Pennesi, PhD | Clinical/Epidemiologic Research | Physiology/Pharmacology | Clinical/Epidemiologic Research

**TIME** | **#** | **MAIN SESSION** | **TITLE** | **LOCATION** | **PRESENTER** | **AUTHOR BLOCK** | **TRACK** | **SCIENTIFIC SECTION**
---|---|---|---|---|---|---|---|---
09:45 AM - 10:00 AM | A0119 | A0119 | The role of VEGF in diabetic retinopathy progression and treatment strategies | Room 100 | Nancy Brons, PhD | Clinical/Epidemiologic Research | Physiology/Pharmacology | Clinical/Epidemiologic Research

**TIME** | **#** | **MAIN SESSION** | **TITLE** | **LOCATION** | **PRESENTER** | **AUTHOR BLOCK** | **TRACK** | **SCIENTIFIC SECTION**
---|---|---|---|---|---|---|---|---
10:00 AM - 10:15 AM | A0120 | A0120 | The role of VEGF in diabetic retinopathy progression and treatment strategies | Room 100 | Nancy Brons, PhD | Clinical/Epidemiologic Research | Physiology/Pharmacology | Clinical/Epidemiologic Research

**TIME** | **#** | **MAIN SESSION** | **TITLE** | **LOCATION** | **PRESENTER** | **AUTHOR BLOCK** | **TRACK** | **SCIENTIFIC SECTION**
---|---|---|---|---|---|---|---|---
10:15 AM - 10:30 AM | A0121 | A0121 | The role of VEGF in diabetic retinopathy progression and treatment strategies | Room 100 | Nancy Brons, PhD | Clinical/Epidemiologic Research | Physiology/Pharmacology | Clinical/Epidemiologic Research

**TIME** | **#** | **MAIN SESSION** | **TITLE** | **LOCATION** | **PRESENTER** | **AUTHOR BLOCK** | **TRACK** | **SCIENTIFIC SECTION**
---|---|---|---|---|---|---|---|---
10:30 AM - 10:45 AM | A0122 | A0122 | The role of VEGF in diabetic retinopathy progression and treatment strategies | Room 100 | Nancy Brons, PhD | Clinical/Epidemiologic Research | Physiology/Pharmacology | Clinical/Epidemiologic Research

**TIME** | **#** | **MAIN SESSION** | **TITLE** | **LOCATION** | **PRESENTER** | **AUTHOR BLOCK** | **TRACK** | **SCIENTIFIC SECTION**
---|---|---|---|---|---|---|---|---
10:45 AM - 11:00 AM | A0123 | A0123 | The role of VEGF in diabetic retinopathy progression and treatment strategies | Room 100 | Nancy Brons, PhD | Clinical/Epidemiologic Research | Physiology/Pharmacology | Clinical/Epidemiologic Research

**TIME** | **#** | **MAIN SESSION** | **TITLE** | **LOCATION** | **PRESENTER** | **AUTHOR BLOCK** | **TRACK** | **SCIENTIFIC SECTION**
---|---|---|---|---|---|---|---|---
11:00 AM - 11:15 AM | A0124 | A0124 | The role of VEGF in diabetic retinopathy progression and treatment strategies | Room 100 | Nancy Brons, PhD | Clinical/Epidemiologic Research | Physiology/Pharmacology | Clinical/Epidemiologic Research

**TIME** | **#** | **MAIN SESSION** | **TITLE** | **LOCATION** | **PRESENTER** | **AUTHOR BLOCK** | **TRACK** | **SCIENTIFIC SECTION**
---|---|---|---|---|---|---|---|---
11:15 AM - 11:30 AM | A0125 | A0125 | The role of VEGF in diabetic retinopathy progression and treatment strategies | Room 100 | Nancy Brons, PhD | Clinical/Epidemiologic Research | Physiology/Pharmacology | Clinical/Epidemiologic Research

**TIME** | **#** | **MAIN SESSION** | **TITLE** | **LOCATION** | **PRESENTER** | **AUTHOR BLOCK** | **TRACK** | **SCIENTIFIC SECTION**
---|---|---|---|---|---|---|---|---
11:30 AM - 11:45 AM | A0126 | A0126 | The role of VEGF in diabetic retinopathy progression and treatment strategies | Room 100 | Nancy Brons, PhD | Clinical/Epidemiologic Research | Physiology/Pharmacology | Clinical/Epidemiologic Research

**TIME** | **#** | **MAIN SESSION** | **TITLE** | **LOCATION** | **PRESENTER** | **AUTHOR BLOCK** | **TRACK** | **SCIENTIFIC SECTION**
---|---|---|---|---|---|---|---|---
11:45 AM - 12:00 PM | A0127 | A0127 | The role of VEGF in diabetic retinopathy progression and treatment strategies | Room 100 | Nancy Brons, PhD | Clinical/Epidemiologic Research | Physiology/Pharmacology | Clinical/Epidemiologic Research

**TIME** | **#** | **MAIN SESSION** | **TITLE** | **LOCATION** | **PRESENTER** | **AUTHOR BLOCK** | **TRACK** | **SCIENTIFIC SECTION**
---|---|---|---|---|---|---|---|---
12:00 PM - 12:15 PM | A0128 | A0128 | The role of VEGF in diabetic retinopathy progression and treatment strategies | Room 100 | Nancy Brons, PhD | Clinical/Epidemiologic Research | Physiology/Pharmacology | Clinical/Epidemiologic Research

**TIME** | **#** | **MAIN SESSION** | **TITLE** | **LOCATION** | **PRESENTER** | **AUTHOR BLOCK** | **TRACK** | **SCIENTIFIC SECTION**
---|---|---|---|---|---|---|---|---
12:15 PM - 12:30 PM | A0129 | A0129 | The role of VEGF in diabetic retinopathy progression and treatment strategies | Room 100 | Nancy Brons, PhD | Clinical/Epidemiologic Research | Physiology/Pharmacology | Clinical/Epidemiologic Research

**TIME** | **#** | **MAIN SESSION** | **TITLE** | **LOCATION** | **PRESENTER** | **AUTHOR BLOCK** | **TRACK** | **SCIENTIFIC SECTION**
---|---|---|---|---|---|---|---|---
12:30 PM - 12:45 PM | A0130 | A0130 | The role of VEGF in diabetic retinopathy progression and treatment strategies | Room 100 | Nancy Brons, PhD | Clinical/Epidemiologic Research | Physiology/Pharmacology | Clinical/Epidemiologic Research

**TIME** | **#** | **MAIN SESSION** | **TITLE** | **LOCATION** | **PRESENTER** | **AUTHOR BLOCK** | **TRACK** | **SCIENTIFIC SECTION**
---|---|---|---|---|---|---|---|---
12:45 PM - 12:00 PM | A0131 | A0131 | The role of VEGF in diabetic retinopathy progression and treatment strategies | Room 100 | Nancy Brons, PhD | Clinical/Epidemiologic Research | Physiology/Pharmacology | Clinical/Epidemiologic Research
### Time Table

**Wednesday, May 3, 2018**

<table>
<thead>
<tr>
<th>Time</th>
<th>#</th>
<th>Main Session</th>
<th>Title</th>
<th>Location</th>
<th>Presenter(s)</th>
<th>Author(s)</th>
<th>Track</th>
<th>Scientific Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 AM - 12:45 PM</td>
<td>A051</td>
<td>Retna</td>
<td>Pathophysiology of vitreous changes with emphasis on clinical-pathologic correlations</td>
<td>Exhibit Hall</td>
<td>Yvonne Lee</td>
<td>Poster Session</td>
<td>Retinal Cell Biology</td>
<td></td>
</tr>
<tr>
<td>11:00 AM - 12:45 PM</td>
<td>A052</td>
<td>Retna</td>
<td>Pathophysiology of vitreous changes with emphasis on clinical-pathologic correlations</td>
<td>Exhibit Hall</td>
<td>Yvonne Lee</td>
<td>Poster Session</td>
<td>Retinal Cell Biology</td>
<td></td>
</tr>
<tr>
<td>11:00 AM - 12:45 PM</td>
<td>A053</td>
<td>Retna</td>
<td>Pathophysiology of vitreous changes with emphasis on clinical-pathologic correlations</td>
<td>Exhibit Hall</td>
<td>Yvonne Lee</td>
<td>Poster Session</td>
<td>Retinal Cell Biology</td>
<td></td>
</tr>
<tr>
<td>11:00 AM - 12:45 PM</td>
<td>A054</td>
<td>Retna</td>
<td>Pathophysiology of vitreous changes with emphasis on clinical-pathologic correlations</td>
<td>Exhibit Hall</td>
<td>Yvonne Lee</td>
<td>Poster Session</td>
<td>Retinal Cell Biology</td>
<td></td>
</tr>
<tr>
<td>11:00 AM - 12:45 PM</td>
<td>A055</td>
<td>Retna</td>
<td>Pathophysiology of vitreous changes with emphasis on clinical-pathologic correlations</td>
<td>Exhibit Hall</td>
<td>Yvonne Lee</td>
<td>Poster Session</td>
<td>Retinal Cell Biology</td>
<td></td>
</tr>
</tbody>
</table>

**Thursday, May 4, 2018**

<table>
<thead>
<tr>
<th>Time</th>
<th>#</th>
<th>Main Session</th>
<th>Title</th>
<th>Location</th>
<th>Presenter(s)</th>
<th>Author(s)</th>
<th>Track</th>
<th>Scientific Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00 AM - 10:30 AM</td>
<td>C001</td>
<td>Ophthalmic surgery: axial approach to Ciliare</td>
<td>Exhibit Hall</td>
<td>T Michael Nork, PhD (moderator)</td>
<td></td>
<td>Poster Session</td>
<td>Retinal Cell Biology</td>
<td></td>
</tr>
<tr>
<td>09:00 AM - 10:30 AM</td>
<td>C002</td>
<td>Ophthalmic surgery: axial approach to Ciliare</td>
<td>Exhibit Hall</td>
<td>T Michael Nork, PhD (moderator)</td>
<td></td>
<td>Poster Session</td>
<td>Retinal Cell Biology</td>
<td></td>
</tr>
<tr>
<td>09:00 AM - 10:30 AM</td>
<td>C003</td>
<td>Ophthalmic surgery: axial approach to Ciliare</td>
<td>Exhibit Hall</td>
<td>T Michael Nork, PhD (moderator)</td>
<td></td>
<td>Poster Session</td>
<td>Retinal Cell Biology</td>
<td></td>
</tr>
<tr>
<td>09:00 AM - 10:30 AM</td>
<td>C004</td>
<td>Ophthalmic surgery: axial approach to Ciliare</td>
<td>Exhibit Hall</td>
<td>T Michael Nork, PhD (moderator)</td>
<td></td>
<td>Poster Session</td>
<td>Retinal Cell Biology</td>
<td></td>
</tr>
<tr>
<td>09:00 AM - 10:30 AM</td>
<td>C005</td>
<td>Ophthalmic surgery: axial approach to Ciliare</td>
<td>Exhibit Hall</td>
<td>T Michael Nork, PhD (moderator)</td>
<td></td>
<td>Poster Session</td>
<td>Retinal Cell Biology</td>
<td></td>
</tr>
</tbody>
</table>

### Abstracts

- **AMD epidemiology and treatment**
  - Exploring factors underlying ethnic differences in Age-Related Macular Degeneration (AMD) prevalence
  - B.usermodel A: Symposium on Retina
  - Symposium on Retina

- **Physiology and Pharmacology**
  - The intrinsically photosensitive retinal ganglion cell (ipRGC)-mediated pupillary light reflex (PLR) as a biomarker of healthy aging
  - The intrinsically photosensitive retinal ganglion cell (ipRGC)-mediated pupillary light reflex (PLR) as a biomarker of healthy aging

- **Multidisciplinary Ophthalmic Imaging**
  - Multidisciplinary Ophthalmic Imaging

- **Low Vision Group**
  - Multidisciplinary Ophthalmic Imaging

- **Clinical/Epidemiologic Research**
  - Association between aqueous humor (AH) and the severity of diabetic retinopathy (DR) in patients with type 2 diabetes mellitus (T2DM)
  - Association between aqueous humor (AH) and the severity of diabetic retinopathy (DR) in patients with type 2 diabetes mellitus (T2DM)
SCORE2 month 6 to month 12 results: 12 month outcomes of treatment change among poor responders at month 6

Michael Ip, MD

Room III

Stacy Meuer, MD

Room III

ARVO HONORS AND LEADERSHIP ACTIVITIES

<table>
<thead>
<tr>
<th>ROLE</th>
<th>NAME</th>
<th>ORGANIZATION/HONOR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Awardee</td>
<td>Amitha Domalpally, PhD</td>
<td>ARVO Foundation 2018 Pfizer Ophthalmics Carl Camras Award</td>
</tr>
<tr>
<td>Honoree</td>
<td>Alice R. McPherson, MD</td>
<td>ARVO Foundation Honoree</td>
</tr>
</tbody>
</table>